Cardiovascular

At first glance the congenital heart questions are a table full of abbreviations — VSD, ASD, PDA, TOF, TGA, TAPVC, Eisenmenger — enough to make anyone dizzy. But remember one thing and half the book falls into place on its own: a heart defect is never merely "a hole in the wall"; it is a rewrite of where the blood is supposed to go. The heart is a two-story house with four rooms (two atria, two ventricles), a few doors (the valves), and two external pipes (the aorta and the pulmonary artery). Every type of congenital heart disease is a variation on "a broken wall, a misfit door, a pipe plumbed to the wrong side." Every classification, every murmur, every timing of cyanosis is a different fork on the same shunt map. Lay the map out first, then walk the blood through it, and every scattered test point will be waiting for you exactly where it should be.

The first axis has only two spokes: shunt direction (left→right vs right→left) decides whether there is cyanosis; shunt location decides which chamber dilates. Hold these two and the murmurs, imaging, and operative timing grow out by themselves.

Memory hook: cyanotic = deoxygenated blood barging straight into the systemic circulation (R→L). Every strange finding traces back to this sentence.

VSD is the most common congenital structural heart defect at birth — and where the hole sits rewrites the entire script.

By location, VSDs come in four types, and each hides an exam-favorite complication or closure rate:

The exam's favorite — "which VSD type goes with AR?" — must never be answered by instinct with "the most common one." Reason it from mechanism, and picture the Venturi effect once so you never forget it: the subarterial hole opens directly beneath the aortic and pulmonary valves. The right coronary cusp normally rests on that fibrous ring like a hammock strung on three ropes; this hole removes the mattress beneath the hammock, and the cusp loses its foundation. Worse, with every systole blood jets at high speed from the left ventricle through the hole toward the right — and by Bernoulli's principle, pressure falls around a fast stream, so a suction cup forms just beneath the right coronary cusp (that is the essence of the Venturi effect: fast flow, low pressure). Beat after beat the cusp is tugged downward → prolapse → the valve no longer closes in diastole → AR. So when you see "VSD + AR," "East Asian patient," or "two murmurs (systolic VSD + diastolic AR)," think subarterial first — not perimembranous. And AR itself is an operative indication: wait too long and the deformed, prolapsed cusp never comes back.

When to repair? One cold number stands at the gate — Qp:Qs > 2:1, pulmonary flow more than double systemic. That means the hole is large and the left ventricle's volume load has reached the point of intervention. Other indications: heart failure refractory to medication, early signs of pulmonary hypertension, failure to thrive. Conversely, a small VSD with Qp:Qs < 2:1 usually closes with age — observation is enough. Remember: "the most common type" is not "the type most needing surgery" — muscular and perimembranous mostly self-close; inlet and subarterial are the surgical mainstays.

With the hole in the atria, the whole tone of the story changes. Left atrial pressure is only slightly above right, so the shunt is neither large nor violent, and the volume overload falls on the right heart. Many patients glide silently into their thirties or forties before anyone hears it. But that auscultated "wide, fixed splitting of S2" is the internal-medicine exam's favorite ambush.

ASD's signature quartet, every item growing from the same mechanism:

• Wide, fixed splitting of S2 — the signature; right-heart filling no longer varies with breathing.
• A systolic ejection murmur at the left second interspace — torrential flow across a normal pulmonary valve, a "relative" stenosis.
• A mid-diastolic murmur at the tricuspid area — torrential flow across a normal tricuspid valve, again "relative" stenosis.
• No loud, split S1 — the thing ASD should *not* produce; a trap option.

ASD also comes in four types, each paired with a specific companion lesion — free marks on the exam:

What you memorize is not the pairing but the *why of the neighborhood*. Primum sits beside the AV valves, so the mitral valve is often cleft along with it — MR. Sinus venosus opens where the cavae come in, squarely on the path of the pulmonary venous return — so a few pulmonary veins go astray (PAPVR). Understand "location decides your neighbors" and you will never pair an inferior sinus venosus ASD with MR.

The last battleground: which side does ASD dilate? Answer: the right heart (RA + RV); the left ventricle carries no volume load. The hole is at atrial level — the extra blood goes to the right heart, through the lungs, back to the left atrium and out; the left ventricle is a *thoroughfare*, not a reservoir. The exact mirror of VSD's left-heart dilation. Do not reverse them.

Total anomalous pulmonary venous connection (TAPVC) is the elegant mechanical puzzle of cyanotic heart disease: all four pulmonary veins bypass the left atrium and drain into the systemic venous system (SVC, the atrium itself, or below the diaphragm). Oxygenated blood cannot reach the left heart, so survival depends on a PFO or ASD to mix — which is precisely why these babies are blue. By drainage route: supracardiac (most common), cardiac, infracardiac (most prone to obstruction), and mixed.

The operative principle is a single mechanism question: find the "vertical vein" that carries pulmonary venous blood to the systemic side, reroute the confluence to the left atrium, and then the vertical vein must be ligated or divided. Why? Leave it open and you have built a postoperative shortcut from pulmonary veins to systemic veins — a man-made, permanent left-to-right shunt that undoes the operation. Any answer choice that says "preserve the vertical vein to maintain collateral flow" is wrong (the exam answer; some centers temporarily leave it open as a pop-off in obstructed cases with a small left heart). Memorize the pair together — reconnect + close the old road — and this question cannot trip you.

Severe AS in an adult means valve replacement — TAVI or surgery, and a mechanical valve can last a lifetime. An infant cannot copy that answer, for two reasons that are pure mechanism: first, an infant's aortic annulus is tiny, and a prosthetic valve does not grow with the child — it may barely fit at implantation and becomes a new stenosis within months, condemning the child to redo surgery every couple of years. Second, mechanical valves demand lifelong warfarin, and an infant cries, bumps, falls, catches fevers and diarrheal illnesses — stable anticoagulation is impossible, and both bleeding risk and dosing burden are unacceptable. So for severe infant AS you choose what can grow up with him.

The management of pediatric SVT pivots on exactly one fork: is the hemodynamics stable?

Two classic traps. First, do not confuse synchronized cardioversion with defibrillation — SVT still has a QRS to synchronize on, so choose sync; defibrillation is for pulselessness/VF. Second, icing the face and pushing adenosine while the pressure is already gone — that hesitation kills. Make "is perfusion stable?" the fork and the rest cannot go wrong.

Back to that newborn in the delivery room — "upper limbs bluer than lower." The phenomenon has an elegant name, reverse differential cyanosis, and it belongs almost exclusively to one disease: d-TGA with a PDA and pulmonary hypertension.

The exam mnemonic is simple: "blue arms → find d-TGA; blue legs → find PDA + pulmonary hypertension." But do not memorize direction alone — reason it from "which ventricle feeds the aorta," and you can rebuild the answer from scratch.

Coarctation of the aorta (CoA) is the archetypal obstructive lesion: the aorta is pinched near the ductal insertion (juxtaductal), just distal to the left subclavian artery. The consequences read straight off the plumbing: high pressure upstream (arms), low pressure downstream (legs) — upper-limb hypertension, weak or delayed femoral pulses (brachiofemoral delay). Take blood pressure in all four limbs and the gap declares itself.

The most reversed fact on exams: is the rib notching superior or inferior? Derive it. With the aorta pinched, blood must reach the lower body through furiously dilated intercostal collaterals. The intercostal artery and nerve run in the costal groove along the inferior border of each rib; years of pounding, dilated collaterals erode that border → inferior notching on X-ray. Follow the anatomical fact — "intercostals run inferiorly" — and "inferior" stops being a memorized token.

As for sex: CoA itself is male-predominant. Do not blur it with Turner syndrome — Turner is an *association*, not CoA's own sex distribution.

Tetralogy of Fallot is the flagship cyanotic disease of pediatrics. Four structures, one mnemonic — PROVe:

Of the four, what actually determines the clinical picture is the degree of PS. Why?

Grasp the resistance balance and tet-spell management needs no memorizing — every move drags the balance back:

• Knee-chest position / squatting: compresses the leg arteries, ↑SVR → blood turns back toward the lungs → the blue lifts. Children discover this instinctively — a TOF child squatting mid-play is not being odd; he is saving himself.
• Oxygen: relaxes the pulmonary vessels, lowers pulmonary resistance.
• Morphine: calms agitation, damps catecholamines, eases infundibular spasm.
• Fluids: raise preload, support the right ventricle.
• Phenylephrine: pure α-agonist, raises SVR — squatting in pharmacological form.

In the womb the fetus depends on the ductus arteriosus bridging the pulmonary artery and the descending aorta — the lungs are not yet breathing, so most right-ventricular blood takes this shortcut past them into the systemic circuit. At birth the lungs open, oxygen tension rises, prostaglandins fall, and the duct closes within hours to days. When it fails to close, that is a patent ductus arteriosus (PDA): after birth aortic pressure > pulmonary pressure → a continuous left-to-right shunt.

The murmur is its most beautiful signature: blood is flowing in both systole and diastole — so you hear a continuous "machinery" murmur below the left clavicle, like a waterwheel that never stops. Alongside it: left-ventricular volume overload, widened pulse pressure, bounding pulses. On CT you see an extra tubular channel between the main pulmonary artery and the descending aorta — quite different from an aneurysm's focal bulge or coarctation's pinched lumen.

The drug question is the exam's favorite direction test, and its mechanism could not be cleaner: the fetal duct stays open because PGE₂ props it open; after birth PGE falls, so the duct closes. Run the chain both ways and you get two drugs pointing in opposite directions:

Back to the newborn with reverse differential cyanosis — this is why the attending said "start PGE₁" without hesitation. Before the arterial switch operation (ASO), a d-TGA baby's entire lifeline hangs on the PDA: close the duct and the two parallel circulations lose their last mixing channel — oxygenation collapses at once. A continuous PGE₁ infusion carries him to an ASO within two weeks of birth. Past two weeks, the left ventricle — accustomed to pumping only the low-pressure pulmonary circuit — deconditions and loses the muscle to drive the systemic circulation; even a perfect anatomical repair then fails, because the pump can no longer carry the load. When needed, a Rashkind balloon atrial septostomy (tearing a hole in the atrial septum) adds atrial-level mixing as a second lifeline beside PGE₁.

The answer to that question is the most important sentence of this chapter: the window has closed — closing the hole now would kill her.

Once Eisenmenger is established, three roads remain: pulmonary vasodilators (bosentan, sildenafil) palliate but never cure; the endgame is heart–lung transplantation; the rest is avoidance — pregnancy, dehydration, altitude — plus IE prophylaxis (these patients sit in the highest-risk group as unrepaired cyanotic disease). On the exam, "close the VSD in an Eisenmenger patient" is always wrong.

Complex congenital disease is often staged: when the infant is too small or the anatomy too tangled, a palliative operation buys time; when growth and physiology allow, the definitive repair follows. What you memorize is not the English names of operations but what each one does on the flow map.

PA banding and the BT shunt are the pair most often reversed — one sentence fixes them: too much lung flow, tie it down; too little, pipe it in. The AVSD infant drowning in pulmonary flow gets a band to tighten the lung road; the severe TOF whose lung road barely passes blood gets a BT shunt borrowed from the systemic side.

Single-ventricle physiology is the final boss. One functional ventricle must serve both circuits, and in the long run that grinds it down. The Fontan pathway dismantles the problem in stages: stage one, the Glenn — sew the SVC directly onto the pulmonary artery so upper-body venous blood drains into the lungs *passively*, never touching the precious ventricle; stage two, the Fontan — bring the IVC to the pulmonary artery as well. The lone ventricle now pumps only the systemic circuit; its workload is halved.

Exam version: "keeping the systemic–pulmonary shunt after a BDG improves survival" — wrong, precisely because two roads into the lungs wear out a single ventricle.

One final three-lesion quick sheet, setting the chapter's most-confused signatures side by side:

The story of the aorta seems far from congenital heart disease, but it is the other end of the same axis: congenital disease asks where the blood should flow; great-vessel disease asks whether the pipe can still hold. When the wall turns brittle and the lumen dilates, any surge of shear can tear the trunk line open, burst it, or split it into two layers. The three topics of this chapter — aortic aneurysm, acute aortic syndrome, and bruits / orthostatic hypotension / chronic venous disease — share one physics: blood crossing an abnormal lumen generates turbulence or shear, and the wall answers with murmur, pain, hemorrhage, or ischemia.

Set thoracic (TAA) and abdominal (AAA) thresholds side by side — one table, but every number has a reason.

Two points the exam loves to swap. First, a 4 cm descending TAA is small — below threshold: the answer is "annual CT surveillance," not surgery; but surveil with CT, not TTE, because echo cannot see the distal descending aorta — a small but heavily tested tool trap. Second, connective-tissue disease (Marfan, Ehlers-Danlos) and bicuspid aortic valve pull the threshold down to 4.5–5.0 cm — these walls are brittle from the start; you cannot wait for 5.5.

The AAA has its own anatomical memory hooks. It favors the segment below the renal arteries (infrarenal), tracks atherosclerosis most closely, and its three great risk factors are male sex, smoking, age > 65. US guidelines: one screening ultrasound for men 65–75 who have ever smoked (Taiwan's direction is similar) — a favorite "health check-up" clue on the boards. Atherosclerotic AAAs are usually > 4 cm, so "most are < 4 cm" is wrong. The rupture triad — abdominal/back pain + hypotension + a pulsatile, asymmetric abdominal mass — once all three line up, do not wait for CT; operate now.

Acute aortic syndrome (AAS) is the umbrella over three neighboring catastrophes that all present as "tearing chest/back pain." The clinical starting point is identical: abrupt onset, tearing quality, radiation to the back, asymmetric pulses, a large inter-arm BP difference — get the CTA.

Every risk factor orbits one axis — brittle wall + high pressure:

The exam loves to slip sick sinus syndrome into the options — it is a rhythm problem with no relation to aortic wall tension, making it the least-related choice. When asked to pick the odd one out, discard it without hesitation.

Dissection carries its own Stanford classification — two guaranteed points on the boards:

Back to the shear question that opened the chapter. Why is the order β-blocker first, then blood pressure?

Back to the chapter's physical axis — blood crossing an abnormal lumen generates turbulence. Its simplest clinical face is the bruit.

Its classic confusion partner is the shunt murmur — the continuous machinery murmur or thrill of an AVM or dialysis fistula. A bruit is "stenosis squeezing out turbulence"; a shunt is "a channel joining two circulations that should be separate" — different mechanism, different meaning. "A bruit indicates arteriovenous shunting" is always wrong.

Now to a seemingly unrelated but equally tested numbers game: orthostatic hypotension.

Memorize the numbers cold — this is a pure gift question:

The trap version reads "SBP↓ 15 / DBP↓ 5" — both short of criteria; don't sign it. Also distinguish vasovagal syncope: prodrome (nausea, sweating, tunnel vision), a trigger (prolonged standing, pain, emotion, the sight of a needle), and rapid spontaneous recovery once down — a different logic from orthostatic hypotension's "stand and drop, sit and recover." The three families behind orthostatic hypotension: autonomic failure (diabetes, Parkinson disease, pure autonomic failure), hypovolemia (dehydration, hemorrhage), drugs (antihypertensives, α-blockers, diuretics, tricyclics).

Arteries narrow, burst, dissect — but the vessel family has a neglected branch: veins. Chronic venous insufficiency (CVI) looks mundane, yet every clinical feature grows from one causal chain.

First-line diagnosis: venous duplex ultrasonography — B-mode anatomy plus Doppler grading of reflux, localizing the failed valves. Risk factors: family history, female sex, pregnancy, prolonged standing, obesity, HRT or oral contraceptives.

Three confusions to puncture: primary varicose veins are strongly familial (often mistaken as non-hereditary); HRT/OCP increase varicose-vein and DVT risk (believing them protective is dead wrong); primary disease lives mainly in the superficial system (great saphenous) (deep involvement is usually secondary — post-thrombotic syndrome after DVT).

ACLS holds endless detail, but this chapter chases only the high-frequency numbers. The physical goal of chest compression is to hold the aorta-to-right-atrium gradient high enough that the coronaries and the brain get blood. The iron rules:

• Rate 100–120/min — slower starves output; faster leaves no time for the heart to refill.
• Depth 5–6 cm (adult) — shallower pumps nothing; deeper breaks ribs.
• Full recoil every compression — thoracic negative pressure pulls blood back to the right heart; no recoil, no filling.
• Minimize interruptions — every pause drops perfusion pressure to zero, and each restart climbs from the bottom.
• Avoid over-ventilation — high intrathoracic pressure blocks venous return; 8–10 breaths/min suffices in adults.
• Monitor end-tidal CO₂ (ETCO₂) — with effective compressions ETCO₂ mirrors pulmonary blood flow; < 10 mmHg means inadequate or futile compressions; a sudden ETCO₂ surge signals ROSC.

Arrhythmias look endlessly varied, but every question opens at the same fork. Not the P waves first, not the QT — look up at the patient first: Is the blood pressure holding? Is consciousness clear? Any ischemic chest pain, acute pulmonary edema, shock? Tick any box and the patient is "unstable" — shelve the differential and go straight to synchronized cardioversion, sedating if needed, hunting the cause while you shock. Conversely, a patient sitting up and negotiating with you — pressure holding, mind clear — is "stable," and you have time: vagal maneuvers first (carotid sinus massage, Valsalva), then adenosine, then verapamil or a β-blocker. Shocking a stable patient with normal pressure is one of the exam's favorite traps — painful, needlessly sedating, and wrong.

Two extensions of this axis. First, the AV node carries dual innervation — so vagal maneuvers are not folklore: carotid massage, Valsalva strain, the diving reflex with ice water all slow AV conduction through the vagus, snapping any reentry loop that runs through the node. Second, stable SVT is never first treated with amiodarone — adenosine owns that slot: an ultra-short half-life, one precise tap on the AV node, effect gone in seconds — safe, and diagnostic and therapeutic at once.

First-line therapy is IV magnesium sulfate — given even when serum magnesium is normal — because magnesium stabilizes L-type calcium channels and suppresses EADs, striking the mechanism itself; then replete potassium to fix the substrate. Refractory cases call for something counterintuitive: speed the heart up. An isoproterenol drip, or temporary overdrive pacing at 100–120 bpm, shortens the RR interval so the QT is proportionally squeezed shorter, narrowing the vulnerable window. This is also why a pacemaker set too slow (say 70 bpm) does nothing for TdP. If TdP is pulseless — defibrillate.

The critical trap is the drug list to avoid. Every QT-prolonging antiarrhythmic is contraindicated in acquired TdP — class Ia quinidine and procainamide, class III sotalol — all pour fuel on the fire. Amiodarone rarely triggers TdP in practice, but it does prolong the QT, and the exam convention is avoid. Lidocaine shortens action-potential duration and can serve as a second-line agent — but never first.

The danger of AF is not the chaotic beat — it is the stagnant blood pooling in the left atrial appendage, waiting to be flung to the brain as a stroke. So AF management runs two lines, "rate" and "anticoagulation," and the anticoagulation decision is scored by CHA₂DS₂-VASc:

Score the 76-year-old: A₂ (≥75) 2 + H 1 + D 1 + Sc 1 = 5 points — far past the threshold. The exam steals points here — dropping the 2 for age ≥ 75, or forgetting the female +1. Men ≥ 2, women ≥ 3 → oral anticoagulation; non-valvular AF takes a DOAC over warfarin, but AF with rheumatic mitral stenosis or a mechanical valve stays on warfarin — no DOAC (this collides again in the valve chapter).

As for aspirin — the most-overturned idea since 2024. Current guidelines no longer endorse aspirin monotherapy for AF stroke prevention: it prevents far less than OAC while bleeding no less. "Just aspirin" is a wrong answer, and the student who stops there loses the point on the spot.

To see why AV block happens, first remember the AV node's dual innervation — the vagus suppresses it, the sympathetics excite it — and its blood supply from the right coronary artery (in most people), which is why an inferior MI with RCA occlusion starves the node at once. Line up "who governs the AV node" and the causes of AV block need no memorizing:

The two cells most often marked backward are hyperthyroidism and α-blockers. Hyperthyroidism is the accelerator direction — faster AV conduction, faster rate, a setup for AF — it does not cause AV block, and it sits in the options precisely to tempt you. α-blockers (doxazosin, tamsulosin) work on vascular smooth-muscle α1 and never touch the AV node; when one appears among "AF rate-control drugs," it is pure filler — rate control means β-blockers, verapamil/diltiazem, digoxin.

The same dual-innervation thread solves a niche but yearly question: the denervated transplanted heart. A donor heart arrives with vagus and sympathetics both severed — denervated — so atropine does nothing: atropine works by blocking the vagal brake, and this heart has no vagus to unblock — a brake pedal wired to nothing. To raise its rate you must press the β1 accelerator directly with catecholamines (isoproterenol, epinephrine) or use external pacing.

Never read an ECG by "what looks weird" — run the sequence, or you will miss. Nail the seven steps and any strip dismantles:

AV block itself is one sentence: watch the relationship between P and QRS. Each degree has a signature move:

• First degree: PR fixed and prolonged > 0.20 s, no beat ever dropped. Usually asymptomatic and chronic.
• Second degree, Mobitz I (Wenckebach): PR stretches progressively until one QRS fails to appear — "dragging until it can't." The block lives within the AV node; mostly benign, usually no pacemaker.
• Second degree, Mobitz II: PR fixed, then sudden drop of a QRS. The block sits below the His-Purkinje junction — a loud warning, prone to complete dissociation, usually needs a permanent pacemaker.
• Third degree (complete block): P and QRS fully dissociated, each on its own clock — the atria at one rhythm, the ventricles on a slower escape at 40–50 bpm; dizziness, dyspnea, exercise intolerance — permanent pacemaker, mandatory.

The mechanistic difference is location: Wenckebach lives in a node that fatigues — hence "drag, longer, drag, drop"; Mobitz II is injured His-Purkinje cable — conduction is all-or-none, hence "PR unchanged, sudden loss." Clinically, a rate of 48 with chest heaviness and P-QRS dissociation on the strip is third-degree AV block — not LVH, not a long QTc, whatever the distractors say.

The QT reflects ventricular repolarization time. Sympathetic drive speeds the rate and repolarization with it — QT shortens; jammed ion channels drag repolarization out — QT lengthens. Sort the causes along that axis:

The thyroid cell is the one most often reversed. Hyper = accelerator = fast rate = fast repolarization = short QT; hypo runs the other way. "Hyperthyroidism prolongs the QT" is a planted decoy — flag it on sight. Digoxin's "scooped" ST depression with a short QT is its signature *effect* (present at therapeutic doses, not toxicity) — a different layer entirely from "digoxin toxicity causes every arrhythmia."

The greatest danger of a long QT is, of course, colliding with TdP from the last section. So when the QTc runs past 500 ms with electrolyte chaos or QT-prolonging drugs aboard, the next move is not another antiarrhythmic — it is check K, check Mg, stop the QT-prolongers, give Mg, have pacing ready.

The ECG keeps a gallery of "signature waves" — recognition equals an instant answer, but each looks the way it does for a reason, and mechanism glues the pairs better than rote.

• Delta wave (short PR, a blunt initial upslope widening the QRS) — WPW pre-excitation. An accessory pathway (bundle of Kent) bypasses the AV node; before the node finishes its polite delay, the accessory road has already pre-excited a patch of ventricle — hence the seemingly short PR and that lazy delta ramp opening the QRS.
• Osborn J wave (a positive hump right after the J point) — hypothermia < 32°C, growing with the cold. Chilled ventricles repolarize unevenly, raising that small dome by the J point.
• Epsilon wave (a tiny spike after the QRS ends) — ARVC (arrhythmogenic right ventricular cardiomyopathy): delayed depolarization from right-ventricular muscle replaced by fat and fibrosis.
• Electrical alternans (QRS amplitude alternating beat by beat) — large pericardial effusion / tamponade. The heart swings in its bath of fluid; its distance to each lead oscillates, and so does the amplitude.
• Peaked T → widening QRS → sine wave — the march of hyperkalemia: tented T first, then QRS widening, then the drowning sine.
• Prominent U waves — hypokalemia.
• Brugada pattern (V1–V3 ST elevation, pseudo-RBBB) — Brugada syndrome, mostly an inherited SCN5A sodium-channel loss-of-function arrhythmia, the notorious killer of young men (especially Southeast Asian) in their sleep. The mechanism chains like this: Na-channel function falls → in the right-ventricular epicardium the phase-1 notch (Ito-dominant) becomes grossly exaggerated, shearing off the phase-2 plateau (loss of dome) → epicardial APs run far shorter than endocardial → a severe transmural repolarization gradient → phase-2 reentry between the layers → polymorphic VT/VF → sudden death. Hence the Type 1 pattern (coved ST ≥ 2 mm in V1–V3 with inverted T) surfaces with fever, Na-channel blockers (Ia, TCAs), hypokalemia, or high nocturnal vagal tone — anything that further suppresses an already weak Na channel. Management after arrest or syncope is an ICD; drugs help little.
• Wellens pattern (deep or biphasic T inversion in V2–V3) — heralds critical proximal LAD stenosis; the patient may be pain-free in clinic, but this morphology is the overture to a massive anterior MI. No stress testing — straight to catheterization.
• de Winter pattern (upsloping ST depression V1–V6 with tall symmetric T waves, slight ST elevation in aVR) — acute proximal LAD occlusion, a STEMI-equivalent: treat as STEMI, immediate PCI.

Two cold but high-yield extras: alternating current (AC) triggers VF more readily than DC, because AC's frequency keeps landing near the T wave's vulnerable window; thallium-201 myocardial perfusion imaging rides the Na⁺-K⁺ ATPase — Tl-201 is a K⁺ analog, pumped into living myocytes, uptake proportional to flow and viability. A stress-phase defect that fills in on delayed images = reversible ischemia (viable muscle); one that persists = scar/infarct. "Reverse redistribution" — normal early, defective late — has limited clinical meaning and is usually tested as a definition.

For recurrent syncope, the evaluation's point is to catch a cardiac cause: ECG, echocardiography (structure), Holter/event recorder, and electrophysiologic study when needed. The planted wrong option is pulmonary function testing — useless for cardiac syncope; strike it on sight.

Chest pain forks the moment the 12-lead is off the printer. ST elevation vs none — first fork; then troponin up or not — second fork. Three answers in a row:

The STEMI iron law: the ECG alone activates the cath lab — never wait for enzymes. Time is muscle. The classic student landmine is "wait for the troponin before deciding" — in STEMI that decision costs myocardium. Oxygen is not unconditional — supplement only when SpO₂ < 90%; nitroglycerin is not the first priority; with a cath lab in the building, primary PCI beats lytics.

With this chain in hand, the four antiplatelet mechanisms stop being a list — each drug strikes one station:

The most-asked mechanism is GP IIb/IIIa: the receptors cannot link each other — fibrinogen must bridge them — so abciximab-class drugs tackle at the finish line. The same chain also settles a side question: does PCI help stable CAD? COURAGE, BARI 2D, ISCHEMIA conclude: in stable angina, PCI versus optimal medical therapy (OMT) improves symptoms and exercise tolerance but does not further reduce MI or death. So stable CAD starts with OMT (antiplatelet + statin + antianginals + risk-factor control), PCI reserved for symptoms drugs cannot hold. Only in ACS does PCI cut death and MI — never mix the two conclusions.

The diagnostic cluster is clean: inferior STEMI + hypotension + JVD + clear lungs, sealed by ST elevation in right-sided lead V4R. And the management has exactly one order:

1. First: rapid fluids (restore preload, hold RV filling pressure).

2. Absolute contraindications: nitroglycerin/nitrates (sublingual, oral, IV), morphine, diuretics — anything preload-lowering is fuel on the fire.

3. Fluids fail → inotropes (dobutamine), IABP; never first-line.

4. The definitive fix remains RCA reperfusion by PCI.

The classic NSTEMI landmine is treating "PCI within 12 hours" as universal — wrong. Only STEMI carries that clock; NSTEMI times its angiography by risk tier:

Two scores to keep apart: TIMI estimates 30-day events in NSTEMI/UA — age ≥ 65, ≥ 3 risk factors, known CAD, aspirin within 7 days, ≥ 2 anginal episodes in 24 h, ST changes, positive markers. GRACE predicts in-hospital and 6-month death more precisely; > 140 crosses into the high tier.

One scene often misread as shock: vasovagal reflex after femoral sheath removal — mechanical stimulus/pain → vagal surge → bradycardia (~40/min) + hypotension. Alarming, but it is vagal overdrive, not hemorrhage: treat with atropine + rapid fluids (flat, legs up) — do not transfuse or re-open for phantom bleeding.

Exercise stress testing has a fixed contraindication list: unstable angina, acute MI < 2 days, uncontrolled severe arrhythmia, severe symptomatic AS, acute PE / myopericarditis, decompensated HF. The distinction to hold: asymptomatic AS is NOT an absolute contraindication — it is relative, testable under monitoring; the exam loves listing it as absolute to trick you.

Auscultation looks like a long table to memorize until you compress it into two questions: is the murmur systolic or diastolic, and is it "flow blocked when it should pass" (stenosis) or "flow leaking when it shouldn't" (regurgitation)? In systole the AV valves are shut and the semilunars open — so a systolic murmur = mitral/tricuspid regurgitation or aortic/pulmonic stenosis. In diastole the AV valves are open and the semilunars shut — so a diastolic murmur = mitral/tricuspid stenosis or aortic/pulmonic regurgitation.

The exam's favorite blind spot: MR is holosystolic, not diastolic — writing MR as pan-diastolic is a pure giveaway trap, and people still fall. And the dynamics principle: right-sided murmurs (TR/PS) grow on inspiration — deeper thoracic negative pressure pulls more venous return into the right heart; HCM and MVP grow on Valsalva/standing (preload ↓), opposite to every other murmur that softens when preload falls.

Normal S2 is A2 (aortic closure) first, P2 (pulmonic closure) second, with physiologic splitting on inspiration — inspiration boosts right-heart return, stretches RV ejection time, delays P2 further, and the A2–P2 gap opens. Hold that dynamic and the three abnormal splits fall into place:

The most-reversed key in paradoxical splitting: the delayed sound is A2 (the aortic valve), never the mitral. Severe AS or LBBB stretches LV ejection until A2 slides behind P2 — so on expiration the pair splits apart, and on inspiration P2 drifts back to merge with A2, the mirror image of physiologic splitting.

The two aortic lesions mirror each other. AS is a cinched outlet: stroke volume capped, systolic pressure unable to climb — narrow pulse pressure; the pulse, filtered through the stenosis, arrives small and late — pulsus parvus et tardus. Under years of load the left ventricle answers with concentric hypertrophy — thick wall, small cavity — which normalizes wall stress and preserves EF, buying years of silence; but once any of the big three — angina, syncope, heart failure — appears, prognosis is measured in years or months, no drug alters the course, and valve replacement (SAVR or TAVR) must be arranged fast.

AR is an outlet still leaking in diastole: diastolic pressure drains fast — wide pulse pressure; the hyperdynamic column slams the peripheral arteries into Corrigan's water-hammer pulse, bisferiens, capillary pulsations. The Austin Flint murmur is severe AR's regurgitant jet striking the anterior mitral leaflet, creating functional mitral narrowing — a mid-to-late diastolic low rumble. It is an accompaniment of AR, not the regurgitant murmur itself — a rumble, not a blow. The wide pulse pressure differential is another regular: AR, PDA, hyperthyroidism, fever, anemia — hyperdynamic or diastolic-leak states; AS is never on that list (its pressure is narrow).

Management: rate control (β-blocker), salt restriction, and percutaneous balloon mitral valvuloplasty when needed. The co-tested pregnancy drug minefield:

Valve-replacement decisions are where memory scrambles. AR's three-door threshold — nail it verbatim:

1. Symptomatic (any LVEF) → Class I.

2. Asymptomatic with reduced LVEF → Class I (2020 AHA/ACC raised the Class I cutoff from 2014's ≤ 50% to ≤ 55% — LVEF ≤ 55% is a clear "operate," not a gray zone).

3. Asymptomatic with LVESD > 50 mm (or indexed LVESDi > 25 mm/m²) → Class 2a; marked LV dilation (LVEDD > 65 mm) → Class 2b.

Worked example: asymptomatic, normal EF, LVESD 30 mm severe AR — far below the 50 mm door, no surgical indication; follow, don't operate. The decoy will claim 30 mm "already needs surgery."

AS runs on one axis: symptoms mean replacement. Severe symptomatic AS (any of angina/syncope/failure, or asymptomatic with EF < 50%) is an indication; drugs never alter the course — do not "observe" a confirmed case. SAVR for the young, low-risk, or those needing concurrent cardiac repairs; TAVR/TAVI, born for high/prohibitive risk, has expanded to intermediate and even low risk with suitable anatomy (PARTNER 3, Evolut Low Risk) — first choice for the elderly or chest-unopenable. "Start antihypertensives/diuretics and watch" is a wrong answer — post-symptom survival runs in years, sometimes months.

MS + AF anticoagulation is Class I. A dilated, stagnant left atrium plus AF means immediate systemic embolic risk; after a stroke, anticoagulation is mandatory — withholding is malpractice. Once more (as in the CHA₂DS₂-VASc section): rheumatic valvular AF stays on warfarin, never DOAC — one of DOAC's few absolute no-go zones. Surgery can pair valve repair + the Maze procedure for the AF.

Following the Ross logic, the whole valve-choice table falls into order:

Ages 50–65 (or 70) are the shared-decision gray zone. One line to carve in stone: mechanical valves anticoagulate with warfarin (VKA) only — DOACs are contraindicated: RE-ALIGN showed dabigatran raising both thrombosis and bleeding on mechanical valves, so DOACs are barred at mechanical valves and rheumatic MS alike.

The final anatomic trap, tested yearly and missed by whole tables: the triangle of Koch beside the tricuspid surgical field hides the AV node. Its borders — the coronary sinus os, the septal tricuspid leaflet attachment, the tendon of Todaro — meet at an apex that is the AV node. A stitch too deep during tricuspid surgery → complete AV block. "Tricuspid surgery needn't worry about AV conduction" is false — this is a maximum-risk zone.

Three beds, three utterly different stories, all orbiting one organ — a fist-sized pump wrapped in a thin two-layered sack, divided into four rooms. If the outer sack strangles the heart, that is pericarditis, tamponade, or constriction; if the chamber muscle itself sickens, that is the four cardiomyopathies; if the pump simply fails, we enter the long war of heart failure. This chapter walks from outside in: first the wrapper (pericardium), then the muscle (myocardium and tumors), and finally the endgame — heart failure and its entire pharmacology, down to transplantation and mechanical support.

Hold this outside-in thread steady, and the scattered test points file themselves.

The pericardium is a two-layered sack: visceral layer hugging the muscle, parietal outside, a film of lubricant between. Inflame it, fill it, or stiffen it, and it shows one of three faces: acute pericarditis, cardiac tamponade, constrictive pericarditis. They look like brothers, but their mechanisms and treatments diverge completely — the exam's favorite family portrait.

Acute Pericarditis: The Chest Pain That Changes With Posture

The "changes with posture" is this section's biggest memory hook. Most pericarditis is idiopathic/viral — the most-tested epidemiologic fact; trainees mis-memorize it as "tuberculous" or "autoimmune," but in most question banks idiopathic/viral (coxsackievirus by name) leads, with TB, uremia, autoimmune disease, radiation, tumor, and drugs trailing.

The ECG also runs a gift-question timeline — the "four stages":

In practice, "diffuse ST elevation + PR depression" is pericarditis until proven otherwise; add the forward-lean relief, supine worsening, and the rub — the classic triad. Troponin may tick up (subepicardial myocardium involved — myopericarditis), but never the dozens-fold surge of STEMI.

Treatment logic returns to "why it hurts." Inflammation drives pain and friction, so NSAIDs (or high-dose aspirin) suppress prostaglandins — first line; colchicine controls the acute attack but above all cuts recurrence — the real reason every guideline lists it first-line. Steroids are not first line — they raise recurrence — reserved for NSAID/colchicine failure, autoimmune disease, or uremic pericarditis. The mnemonic is simple: NSAID + colchicine, twin blades; steroids are the reserve, never the opening move.

Tamponade vs Constrictive Pericarditis: One Sack, Two Stranglings

If the pericardium is a cord, tamponade is "a balloon burst-filled with water in minutes," constriction "a plaster shell hardening over years." Both strangle filling — but the manner, the speed, and the hemodynamic signatures differ completely, which is why the boards frame them together.

The most-tested divide lies in two respiratory signs — pulsus paradoxus and the Kussmaul sign.

Normally, inspiration deepens thoracic negative pressure and boosts right-heart return; the same negative pressure dilates the pulmonary vascular pool so left-heart return dips — and systolic pressure normally falls no more than 10 mmHg. In tamponade, the pericardial space is water-packed: the swelling right heart shoves the septum into the left ventricle, compressing it further — so inspiratory systolic pressure falls beyond 10 mmHg: pulsus paradoxus. The Kussmaul sign (JVP *rising* on inspiration) means "the right heart cannot accept extra return" — so it appears in constriction, severe RV infarction, severe TR — the rigid-right-heart club — and precisely not in tamponade. Why? Because tamponade's fluid loads the whole pericardium uniformly; inspiration shifts all chamber pressures together, and the right heart is not selectively walled off.

The jugular waveform is another regular. Venous pressure has two descents — X (after atrial systole) and Y (after tricuspid opening):

That "constrictive RV systolic usually < 50 mmHg" is the detail most often missed — the filling failure comes from the shell outside; the pulmonary circuit itself is healthy, so RV pressure never climbs to the 70s and 80s of true pulmonary hypertension. Given a constrictive patient with RV systolic 30 and PA pressure 30 — do not call it pulmonary hypertension.

And Beck's triad's most common trap is smuggling in Kussmaul or the friction rub — the triad is exactly three: hypotension, JVD, distant heart sounds. Kussmaul belongs to constriction, the rub to acute pericarditis.

Management splits cleanly: tamponade takes emergency pericardiocentesis to save the hour; constriction takes pericardiectomy to cure. Diuretics relieve constriction's congestion but make tamponade worse — draining volume from a heart already strangled.

Hypertrophic cardiomyopathy (HCM) heads the list of exercise sudden deaths in the young, and it is the boards' flagship example of counterintuitive responses to bedside maneuvers. To read it, first think through *why this heart plugs itself.*

With "emptier is tighter" understood, every maneuver derives itself:

From which the treatment iron law falls out: everything that shrinks the ventricle is contraindicated.

The forbidden trio resurfaces on exams as "give furosemide plus nitrate plus digoxin" — three landmines in one stem; hold "emptier is tighter" and you strike out all three automatically. β-blockers lead because they do three favorable things at once: slower rate lengthens diastole (a fuller chamber empties less), lower contractility (less leaflet suction), lower oxygen demand.

Histologically HCM's hallmark is myofiber disarray plus interstitial fibrosis — fibers that should lie parallel instead knot and crisscross, the sharpest contrast with DCM (stretched but still orderly). Clinically the hypertrophy usually emerges in adolescence, not at birth; about 3–8.5% (commonly cited 3–5%, in any case < 10%) convert years later (often ~14 years after symptoms) to a burned-out phase — the thick muscle fibroses, walls thin, EF ≤ 50%, the picture drifting toward DCM. Sudden-death risk markers: family history of SCD, unexplained syncope, nonsustained VT, wall ≥ 30 mm, flat exercise BP — high-risk patients get an ICD.

The auscultatory signature is the tumor plop — in diastole the mass surges into the mitral orifice, knocks the annulus with a low "plop," then dams the flow into an MS-like diastolic rumble. Unlike true MS, both the plop and the rumble shift with position — the origin of its double name, "positional syncope, positional murmur."

Epidemiology details recur: myxoma favors women (~2:1); a minority belong to the Carney complex (skin pigmentation, endocrine overactivity, multiple myxomas). The commonest primary cardiac tumor of childhood is not myxoma but rhabdomyoma, associated with tuberous sclerosis — never swap the adult and pediatric champions. The diagnostic tool is a gift question: echocardiography first (transthoracic or transesophageal) — you watch the stalked, swaying mass directly; CT/MRI are adjuncts; blood tests show only nonspecific ESR and IL-6 elevation.

One iron rule of management: myxoma with embolism or obstruction → surgical excision — never anticoagulation alone. The tumor itself is the embolic source; anticoagulants merely delay while it keeps growing and shedding. The cure is excision, stalk and root; prognosis is excellent, recurrence low (familial and Carney cases excepted).

The four types are really a 2×2 — is the chamber dilated or thickened? is the failure systolic or diastolic? — plus one special corner (ARVC). Fix the grid and etiologies and biopsies snap into place.

One-line summary: DCM "can't pump" (balloons out); HCM "too stiff to fill" (plugs itself); RCM "stuffed rigid by intruders"; ARVC "right-ventricular muscle turned to fat, firing wild."

DCM's tested details: doxorubicin dose-dependent cardiotoxicity, alcoholic cardiomyopathy, TTN (titin) mutations as the commonest single-gene cause, peripartum cardiomyopathy (within a month of delivery; Black women, twins, advanced age at risk); histology shows "stretched but orderly" fibers with abundant interstitial fibrosis — no HCM disarray. ARVC is the other young-athlete killer (alongside HCM); biopsy shows right-ventricular myocardium replaced by fat and fibrosis — desmosome mutations uncouple the cells, and fat fills where myocytes died.

Cardiac Amyloidosis: Thick Walls, Low Voltage

Two main types to separate:

Ultrastructure: non-branching fibrils ~7.5–10 nm (nanometers, not microns), and apple-green birefringence on Congo red — pathology's signature stamp. Clinical triggers: unexplained HFpEF in the elderly, thick walls with low ECG voltage, and extracardiac clues — macroglossia or a carpal tunnel history (the deposits roam nerves and soft tissue too).

Myocardial Infarction: Time, Histology, Complication

Not strictly this section's turf, but the MI "histologic timeline" and *why rupture picks its day* extend cardiac pathology — and the boards adore it.

The "three ruptures" differential: free wall → tamponade; septum → new left-sternal holosystolic murmur + shock (L→R shunt); papillary muscle → new apical holosystolic murmur + pulmonary edema (acute MR). All three cluster at days 3–7. ST still elevated past 2 weeks points to ventricular aneurysm — scar mechanics that never let the ST return home.

Degenerative vs Rheumatic Valve Disease

One last slab of valve pathology — a biopsy gift question.

One line settles it: fused commissures = rheumatic; nodular calcification without fusion = degenerative. The rheumatic Aschoff body is a granuloma — central fibrinoid necrosis ringed by Anitschkow histiocytes (caterpillar or owl-eye nuclei) and lymphocytes — acute rheumatic fever's autoimmune fingerprint on muscle and valve.

The favorite stem: "used to carry goods 10 trips before tiring, now 5, comfortable at rest" — which class? Class II (symptoms at moderate exertion) — routinely mis-filed as III.

The Four Pillars: Only Survival-Proven Drugs Count

Note the β-blocker fine print — only carvedilol, bisoprolol, metoprolol succinate carry HFrEF survival evidence. The planted error is propranolol — no HFrEF evidence (nonselective, short-acting). Mnemonic: "Car-Bi-Met."

Beyond the pillars, the symptom-only drugs must never masquerade as life-savers:

The contraindication is mandatory: HFrEF bans non-dihydropyridine CCBs (verapamil, diltiazem) — powerful negative inotropes pressing down on a pump already failing. The decoy offers "verapamil for the rate" — HFrEF rate control goes through β-blockers or ivabradine, never non-DHP CCBs.

BNP / NT-proBNP: The Truth About That ARNI Patient

Back to the patient whose BNP rose. She fears deterioration — but in fact —

The obesity trap recurs too — adipocytes over-express the NPR-C clearance receptor, pulling circulating BNP in for destruction, so obese patients run low. In an obese dyspneic patient, BNP 100 excludes nothing; lean on clinical picture and echo. Conversely renal failure, age, female sex, and AF push BNP up — an 80-year-old with AF at BNP 400 is not automatically in acute failure.

Physical Signs: The Most Useful and the Least

Not every sign earns its keep. S3 gallop, JVD, hepatojugular reflux, orthopnea, basal crackles, pitting ankle edema, congested liver all carry different weights — S3 and JVD are the most specific for left failure, with orthopnea close behind.

An RV heave, by contrast, reflects RV hypertrophy/pulmonary hypertension — in a patient already known to have left failure plus mitral stenosis, it is merely the logical downstream consequence, adding the least to the diagnosis. When the boards ask "which sign helps least here," the answer is usually the RV heave.

Cardiovascular pharmacology crushes by volume — until you string it on one axis: target → mechanism → direct or indirect. Then every drug hangs on a single family tree.

Anticoagulants: Which Target, and Through AT-III or Not

Warfarin's two high-frequency traps. First, it is initially procoagulant — proteins C and S have shorter half-lives than II/IX/X, so anticoagulant proteins fall first and the first days actually favor thrombosis (up to warfarin-induced skin necrosis) — hence bridge with heparin until the INR settles. Second, warfarin crosses the placenta and is teratogenic (chondrodysplasia) — banned in pregnancy; switch to LMWH.

The DOAC trap: banned at mechanical valves and severe mitral stenosis — thrombosis there runs on high shear and atrial stasis, where DOAC trials failed; only warfarin is proven.

Antiplatelets: Four Different Stations

The recurring asks: which line does abciximab walk — the final common pathway (GP IIb/IIIa), not ADP; and vorapaxar is PAR-1 (thrombin receptor) — a class of its own.

Antihypertensives by Site of Action

Many drugs, one clean logic — split along BP = cardiac output × peripheral resistance: lower the output, or lower the resistance.

The asks cluster on "whose mechanism is this": felodipine = DHP-CCB, L-type calcium channel; hydralazine = direct arterial dilator (not venous — that is nitrates); clonidine = central α₂ agonist (not peripheral α₁ antagonist).

The Natriuretic System and the Two Roads of Neprilysin Inhibition

The favorite rewrite calls nesiritide or sacubitril "positive inotropes" — wrong. They are natriuretic-peptide drugs, cGMP not cAMP, no added contractility. The inotropes are dobutamine (β₁) and milrinone (PDE3 inhibition), both cAMP. Same directional trap elsewhere — NO and nitrates ride cGMP (NO → guanylate cyclase → cGMP → smooth-muscle relaxation); stems that say cAMP are wrong.

The Ductus, Operated Both Ways

One last item straddling medicine and surgery — the ductus arteriosus opens and closes on prostaglandins.

• To close (preterm PDA): ibuprofen/indomethacin (COX inhibitors) → PGE₂ ↓ → the duct constricts shut.
• To keep open (duct-dependent cyanotic disease such as d-TGA): PGE₁ (alprostadil).

The favorite trap sends surgically correctable congenital disease to transplant — a violation of last-resort, hence contraindicated. The overlooked one is irreversible pulmonary hypertension: the donor's right ventricle arrives at normal thickness and cannot suddenly face those stiff, high-resistance lungs — such patients go to combined heart-lung transplant, or first trial vasodilators.

The Modern Alternative: LVADs Are No Longer Science Fiction

End-stage failure is not "transplant or nothing." The LVAD now plays two roles:

• Bridge to transplant (BTT): sustaining life on the waiting list.
• Destination therapy (DT): for transplant-ineligible patients (age, comorbidity), the LVAD *is* the endgame.

In acute decompensation (cardiogenic shock), two short-term bridges: IABP and ECMO.

IABP timing is a gift question — but own the mechanism:

The classic rewrite — "deflates in mid-diastole, inflates in systole" — is wrong. Deflation is the instant before systole; inflation spans diastole. Triggering runs off the ECG R wave or the arterial dicrotic notch. Contraindications: aortic regurgitation (inflation worsens the leak), aortic dissection, severe peripheral arterial disease.

The Lesson of STITCH: Smaller Volume ≠ Longer Life

Finally, a surgical idea widely misremembered. The STITCH trial (Surgical Treatment for Ischemic Heart Failure; NEJM 2011/2016 long-term) compared CABG alone vs CABG + surgical ventricular restoration (SVR).

The tested claim: "CABG + ventricular restoration improves symptoms and survival" — the second half is false; survival never beat CABG alone.

Two lessons: first, heart-failure therapy still rests on the four pillars, not on surgically shrinking the chamber; second, "smaller volume" and "longer life" are different things — a smaller chamber may be geometry, not healed muscle.

Primary Cardiac Tumors: Mostly Benign, Mostly Metastatic

To close the section: primary cardiac tumors are rare — under a twentieth of metastatic involvement — the common cardiac tumor is the one that traveled in (lung, breast, lymphoma, melanoma metastases far outnumber primaries). Among primaries, ~75% are benign; the malignant remainder is mostly angiosarcoma or lymphoma. The benign champion is the myxoma we met above; in children, rhabdomyoma (tuberous sclerosis).

Lipids and blood pressure are called silent killers not because they are mysterious but because they speak in numbers, not symptoms — and every lethal number can be explained by a chain of cause and effect. This chapter memorizes no jingles; it strings every test point onto a few spines — how lipoproteins travel, where pressure comes from, and why an antihypertensive collides with renal artery stenosis.

Four routes memorized, half the questions solved: chylomicron = gut → TG → periphery; VLDL = liver → TG → periphery; LDL = cholesterol outbound; HDL = cholesterol homebound. LDL is the villain because it stuffs cholesterol into vessel walls; HDL the sweeper because it hauls it back. The swapped-enzyme trap: TG hydrolysis is LPL's job; HDL's esterification is LCAT's — "break TG apart for tissues" versus "lock cholesterol into the HDL core," two different reactions endlessly interchanged as decoys.

Here hides the deadly co-trap: above TG 1,000 mg/dL the true danger is not atherosclerosis — it is acute pancreatitis. Extreme TG lets pancreatic enzymes generate locally toxic fatty acids and clog the microcirculation — the pancreas digests itself. So the eruptive-xanthoma patient's first order of business is not a ten-year risk calculator: it is TG control to fend off pancreatitis, fibrates first, and absolutely no bile-acid resins — they *raise* TG.

The Fredrickson classification simply maps "which lipoprotein rose" onto "did TG or cholesterol rise." With the lipoprotein spine in place, the five types derive themselves:

Two must-hold types: IIa is familial hypercholesterolemia — the 18-year-old's tendon xanthomas; IV is the commonest primary hyperlipidemia — obesity/diabetes/metabolic syndrome, TG-led. III is the rare apoE2/E2 palm-stripe club — "palms = III" suffices. I and V share extreme TG and pancreatitis; atherosclerosis is not their stage.

ACC/AHA's four statin populations — remember "diseased, sky-high, diabetic, high-risk":

1. Established ASCVD (CAD/stroke/PAD — secondary prevention) → high-intensity statin. LDL target: very-high-risk < 55 mg/dL (ESC), high-risk < 70. Add non-statin drugs at LDL ≥ 70.

2. LDL ≥ 190 mg/dL (suspect FH) → high-intensity.

3. Diabetes, age 40–75, LDL 70–189 → at least moderate.

4. 10-year ASCVD risk ≥ 7.5% → moderate-to-high.

"High" and "moderate" intensity are defined not by milligrams but by target LDL reduction: high ≥ 50% (atorvastatin 40–80, rosuvastatin 20–40), moderate 30–49%. One line: read the percent drop, not the mg.

The lipid drugs all strike stations on one synthesis-clearance chain. Statins inhibit HMG-CoA reductase; the emptied hepatic cholesterol pool activates SREBP-2, LDL receptors are massively upregulated → blood LDL captured and degraded → LDL plunges. The most-tested side effect is myopathy/rhabdomyolysis, with the proposed mechanism that blocking HMG-CoA drains the mevalonate pathway's downstream CoQ10 (ubiquinone) and isoprenoids — muscle mitochondria lean hardest on CoQ10; deprived, the electron chain falters, fiber membranes destabilize, enzymes leak. Hence the risk spikes with fibrates (gemfibrozil interferes with statin handling via OATP), CYP3A4 inhibitors (grapefruit juice, erythromycin), or renal impairment. Ezetimibe blocks the gut's NPC1L1 cholesterol channel, cutting the exogenous supply — additive with statins. PCSK9 inhibitors must be reasoned in reverse: PCSK9 is the hepatocyte's own "LDL-receptor demolition crew" — co-internalized with the receptor, it drags it into the lysosome so it cannot recycle to the surface. More PCSK9 → fewer receptors → higher LDL. Humans with PCSK9 loss-of-function mutations (commoner in African ancestry) carry a broken demolition crew: receptors escape destruction, recycle more, crowd the surface, clear LDL over and over → lifelong low LDL and sharply lower ASCVD risk — the entire rationale for the target, with evolocumab/alirocumab as engineered mimics of that LOF. Fibrates activate PPARα, raise LPL activity, and slash TG — first choice against pancreatitis-level TG, at the price of gallstones and statin-myopathy potentiation (gemfibrozil worst). Niacin suppresses hepatic VLDL synthesis; its flush is PGD2-mediated — pre-dose aspirin prevents it. Bile-acid resins trap bile acids and force the liver to spend cholesterol — but raise TG: banned in hypertriglyceridemia. The grapefruit trap: only CYP3A4-metabolized statins are hit (simvastatin, lovastatin, atorvastatin) — juice inhibits the pathway, levels climb, muscle toxicity rises; pravastatin and rosuvastatin bypass CYP3A4 and shrug it off — prefer them in polypharmacy.

The staging thresholds look like number-memorizing, but each society is really asking "from which threshold does lowering reduce events?" ACC/AHA 2017 pulled the line down to 130/80 precisely because SPRINT showed aggressive lowering benefits the high-risk:

Europe's ESC/ESH keeps ≥ 140/90 as the diagnostic line; Taiwan's 2022 guideline takes a third road, setting the home blood-pressure threshold at ≥ 130/80 (home, not office), on the argument that home readings dodge the white-coat effect and reflect the truth. Read which rulebook the question cites — the answers differ completely. And diagnosis never rests on one reading: multiple days, or home/24-hour ambulatory monitoring.

Some ninety-plus percent of hypertension is primary (essential) — no single nameable cause, just genes, sodium, sympathetics, RAAS, and renal regulation drifting out of balance for years. But when the stem hands you "young (< 30), abrupt, resistant (three drugs and still up), plus a specific clue," turn toward secondary disease. Its value is curability — find the cause and the pressure problem can be solved at the root.

One direction that flips in memory: the ACEI's electrolyte side effect is hyperkalemia, not hypokalemia — AngII blocked → aldosterone ↓ → the collecting duct keeps potassium. "Low potassium" is no ACEI contraindication; it is, rather, the clue of a secondary cause (primary aldosteronism).

Pregnancy is its own column, fetal safety first: labetalol, nifedipine, methyldopa lead; ACEI/ARB absolutely banned (fetal renal dysgenesis, oligohydramnios, calvarial defects).

This chapter memorizes no fragments. It asks three questions to the root — why blood flows the way it does, why the embryo grew exactly these great vessels, and why arterial conduits outlast venous ones — and lets the mechanical system of the circulation explain itself.

The exam digs two holes: first, stems quote diameter — convert to radius yourself; second, fourth power, not squared. Hold both and the calculations are free points. Viscosity follows the formula too: polycythemia raises η and lowers Q — hence the thrombosis and the hypoxia.

Wire the physics into physiology: MAP = CO × TPR — total peripheral resistance is essentially "average vessel radius," tuned by sympathetics, local metabolites (CO₂, lactate, adenosine), and hormones. And MAP ≈ DBP + ⅓ pulse pressure, *not* (SBP+DBP)/2 — diastole occupies the greater share of the cycle, so the mean leans diastolic; a routinely missed point.

The Frank-Starling curve rises, then rolls over: preload up → SV up — past a point, down — the physical substrate of exhausted compensation in failure. Exercise multiplies CO four- to five-fold via greater venous return (respiration, muscle pump), sympathetic HR and contractility, and skeletal-muscle arterial dilation dropping TPR — MAP barely rises while pulse pressure widens.

Acute AR (endocarditis, a dissection shearing the valve) is another creature entirely — the ventricle has had no time to dilate; the flood pours in at once, end-diastolic pressure explodes, pulmonary edema, shock — an emergency. So "acute vs chronic" and "volume vs pressure" are two separate axes; never cross-wire them.

Chronic AR's compensation carries one more tested point: with effective CO down, RAAS activates, sodium and water are kept → volume rises, preload rises → Frank-Starling pulls SV back. The correct direction is "volume up"; the decoy writes "the kidneys dump salt, ANP diureses" — which would shrink volume and undo the compensation, the exact opposite of the body's intent.

Reverse it: pressure falls (standing up, bleeding, vasodilation), firing slows, the center lifts sympathetics and drops the vagus → constriction, faster rate, more contractility — pressure propped back up. Orthostatic hypotension's criterion: within 3 minutes of standing, SBP falls ≥ 20 mmHg or DBP ≥ 10 (either suffices) — "20/10, 3 minutes."

The point to hold: the ascending aorta and pulmonary trunk themselves are NOT arch derivatives — they arise from the truncus arteriosus of the bulbus cordis, spiraled into two channels by neural-crest-assisted septation. The arches contribute only the branches beyond.

One clinical mechanism rides along — differential cyanosis: with a persistent PDA and high pulmonary vascular resistance (persistent pulmonary hypertension of the newborn), deoxygenated pulmonary blood streams backward through the duct into the descending aorta — blue lower body, pink upper. It picks the lower body because the PDA joins the aorta beyond the arch — exactly the territory the descending aorta feeds.

Two drug directions in the clinic: a preterm PDA that will not close gets indomethacin/ibuprofen (prostaglandin synthesis inhibition); a duct-dependent congenital lesion (hypoplastic left heart, pulmonary atresia) needs IV PGE₁ to keep the duct open — the circulation's only road. Never reverse them.

The point: the pleuropericardial membranes carried the phrenic nerve and common cardinal vein along as they folded — which is why the adult phrenic nerves run down either side of the fibrous pericardium to the diaphragm, a landmark cardiac surgery must know. The exam's trap wires the pleuropericardial membrane to the serous visceral layer — the correct wiring is pleuropericardial membrane → fibrous pericardium; remember "pleuropericardial = fibrous + phrenic."

As for the Purkinje fibers — the conduction system's fast last mile — they are specialized cardiomyocytes, not neurons (despite the neural-sounding name). Their profile: large cells, glycogen-rich, few myofibrils, few intercalated discs, fastest conduction — built to fling excitation across the ventricles. Asked their origin, answer specialized cardiac muscle.

Ranking chant: LIMA-LAD ≫ RIMA ≫ radial > SVG.

Taking both IMAs (BIMA) adds a second arterial conduit and improves long-term survival — at the cost of the sternum's blood supply, which those two arteries provide. Harvest both and the sternum runs ischemic, wounds heal poorly, and deep sternal wound infection (mediastinitis) risk climbs. BIMA therefore avoids the poor-healing, infection-prone:

Note: inhaler-treated COPD is not itself a BIMA contraindication (a standing decoy) — the true keys are sternal-healing risk factors.

On-pump (arrested-heart, cardiopulmonary bypass) is the tradition: still heart, machine-run circulation, a stable field, the most complete grafting — at the price of bypass-machine complications: systemic inflammation, neurologic injury, acute kidney injury, bleeding. Off-pump sews on the beating heart, skipping the machine and, in theory, its complications. But the large RCTs found no long-term off-pump advantage: CORONARY (experienced surgeons) showed 5-year equivalence; ROOBY (less experienced) showed off-pump with lower 1-year patency, worse 5-year survival and event-free survival, and less complete revascularization. One line: off-pump is at best "equivalent," worse in inexperienced hands, and never patency-superior.

The exam plants "off-pump has better patency" as a false statement — the truth is no long-term advantage (equal or worse).

One last frequently reversed point. In heart failure/AF, digoxin controls the ventricular rate and improves symptoms (the DIG trial), but has never been shown to lower mortality — some subgroup analyses even suggest harm at high serum levels. Mortality belongs to the four pillars — ACEI/ARNI, β-blockers, MRA, SGLT2 inhibitors — and digoxin is not among them. The exam offers "digoxin lowers mortality" as a false statement — remember: symptoms improve, mortality does not.